The Global Plasmid DNA Manufacturing Market Growth Accelerated By Increasing Adoption Of Gene And Cell Therapies
Plasmid DNA is used in the manufacture of gene therapy and DNA vaccines. It has advantages like high efficiency and specificity. With growing demand for gene and cell therapies in treating cancer and other diseases, there is an increasing need for plasmid DNA in research and development.
The global Plasmid Dna Manufacturing Market is estimated to be valued at Us$ 901.2 Billion In 2023 and is expected to exhibit a CAGR Of 4.8% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Rising investment and partnership in research and development of gene therapies is accelerating the growth of plasmid DNA manufacturing market. Several pharma giants are investing heavily and collaborating with academic institutions and biotech companies to develop advanced gene therapies. For instance, Novartis partnered with Massachusetts Eye and Ear and Massachusetts General Hospital to develop gene therapies for inherited retinal diseases. Such investments and partnerships are focused on bringing more plasmid DNA based gene therapies to the market which is expected to boost the demand for plasmid DNA and drive the market growth over the forecast period.
Segment Analysis
The global plasmid DNA manufacturing market is dominated by the clinical trials segment. This segment accounts for the major share owing to the increasing number of clinical trials for cell and gene therapies globally. The increasing number of gene therapy clinical trials offer a multitude of growth opportunities for companies offering plasmid DNA manufacturing services to support various stages of clinical development.
Key Takeaways
The Global Plasmid DNA Manufacturing Market Demand is expected to witness high growth over the forecast period of 2023-2030. The global Plasmid DNA Manufacturing Market is estimated to be valued at US$ 901.2 billion in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
The North America region currently dominates the global plasmid DNA manufacturing market. This is attributed to factors such as presence of key market players, increasing R&D budgets for drug development, growing biopharmaceutical industry, and rising prevalence of cancer and infectious diseases in the region. The Europe region is also expected to witness significant growth in the plasmid DNA manufacturing market supported by favorable government initiatives and funding for research.
Key players
The key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., and Aldevro. Cobra Biologics offers plasmid DNA services such as process development, plasmid manufacturing, and analytical testing with proven capabilities in developing and manufacturing DNA products for clinical applications. VGXI, Inc. provides plasmid DNA manufacturing, purification, and testing services supporting various stages of clinical development for gene and cell therapies. Aldevro specializes in plasmid DNA manufacturing for gene therapy, DNA vaccines, and other applications with capabilities to produce DNA at clinical and commercial scale.
Get more insights on this topic :